Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
The addition of chemotherapy to targeted therapy prolonged overall survival and PFS in patients with EGFR mutant NSCLC; toxicity was increased but overall quality of life was not impacted.